Antiretroviral Therapy in India (2025): Drugs, Indications, Contraindications, Mechanisms, and Prophylaxis (PEP/PrEP)
Journal of The Association of Physicians of India · 2026-06 · 74 (6) · 88-92
DOI: 10.59556/japi.74.1559 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of The Association of Physicians of India, 2026-06. Verfasst von Rajesh Deshwal. Beteiligte Einrichtung: Professor, Department of Emergency Medicine, Pacific Medical College and Hospital, Udaipur, Rajasthan, India, Corresponding Author. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: India has made major gains in HIV control, with nationwide scale-up of antiretroviral therapy (ART), routine viral load monitoring, and simplified dolutegravir-based regimens. Yet gaps persist in differentiated service delivery, drug-resistance surveillance, and prevention implementation (PEP/PrEP). OBJECTIVES: To provide a comprehensive, India-focused review of currently available antiretroviral drugs and fixed-dose combinations (FDCs), indications and contraindications for ART initiation, core mechanisms of action by class, regimen selection and monitoring, and detailed, practical guidance on HIV postexposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP), with attention to 2024-2025 updates. METHODS: Narrative review of national guidance (NACO), WHO recommendations, and key implementation documents and peer-reviewed Indian literature (2018-2025), emphasizing policy-relevant updates and practical algorithms. KEY FINDINGS: DCGI approved TDF/FTC for PrEP; national technical guidance exists, but programmatic rollout remains uneven. Global prevention options expanded with FDA approval (June 2025) of twice-yearly injectable lenacapavir for PrEP. Indian availability will depend on future regulatory decisions and access arrangements. CONCLUSION: India's ART platform is strong and increasingly INSTI-based. Scaling PrEP, standardizing DTG-aligned PEP, fortifying viral load and resistance monitoring, and integrating long-acting prevention as it becomes available are the next priorities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Professor, Department of Emergency Medicine, Pacific Medical College and Hospital, Udaipur, Rajasthan, India, Corresponding Author.
Zitieren
APA
Deshwal, R. (2026). Antiretroviral Therapy in India (2025): Drugs, Indications, Contraindications, Mechanisms, and Prophylaxis (PEP/PrEP). Journal of The Association of Physicians of India, 74(6), 88-92. https://doi.org/10.59556/japi.74.1559
Vancouver
Deshwal R. Antiretroviral Therapy in India (2025): Drugs, Indications, Contraindications, Mechanisms, and Prophylaxis (PEP/PrEP). Journal of The Association of Physicians of India. 2026;74(6):88-92. doi:10.59556/japi.74.1559
BibTeX
@article{Deshwal2026,
author = {Deshwal, Rajesh},
title = {Antiretroviral Therapy in India (2025): Drugs, Indications, Contraindications, Mechanisms, and Prophylaxis (PEP/PrEP)},
journal = {Journal of The Association of Physicians of India},
year = {2026},
volume = {74},
number = {6},
pages = {88--92},
doi = {10.59556/japi.74.1559}
}
EUVIMED